Investment Thesis
Nexalin is a pre-revenue stage medical device company with unsustainable cash burn of $1.7M per quarter against only $14.9K in quarterly revenue, resulting in negative operating cash flow and a sub-4 month cash runway at current burn rate. Despite exceptional 87.8% gross margin, operating losses of $2.1M dwarf revenue generation, indicating the company faces near-term solvency risk without significant capital infusion or dramatic revenue acceleration.
Strengths
- Strong gross margin of 87.8% indicates product-market value proposition
- Zero debt and clean capital structure with $1.2M cash on hand
- Exceptional 3,760.8% YoY revenue growth (though from negligible base of $14.9K)
Risks
- Critical cash burn: -$1.7M operating cash flow vs. $1.2M total cash = <4 months runway
- Severe operating losses of -$2.1M on minimal revenue creates -14,179.9% operating margin
- Pre-commercial stage with no evidence of sustainable path to profitability or significant customer adoption
- Zero insider Form 4 filings in 90 days suggests lack of management confidence or activity
Key Metrics to Watch
- Quarterly revenue run rate and customer acquisition trends
- Cash balance and monthly burn rate to track solvency runway
- Operating expense reductions or capital raise announcements
Financial Metrics
Revenue
15.0K
Net Income
-2.1M
EPS (Diluted)
$-0.11
Free Cash Flow
-1.7M
Total Assets
3.7M
Cash
1.2M
Profitability Ratios
Gross Margin
87.8%
Operating Margin
-14,179.9%
Net Margin
-14,025.7%
ROE
-72.6%
ROA
-56.8%
FCF Margin
-11,458.1%
Balance Sheet & Liquidity
Current Ratio
4.07x
Quick Ratio
3.85x
Debt/Equity
0.00x
Debt/Assets
21.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:54:49.668125 |
Data as of: 2026-03-31 |
Powered by Claude AI